All articles by Clinical Trials Arena Team
Clinical Trials Arena Team
Pipeline Moves: Novo Nordisk Phase III semaglutide completion bumps approval prospects
The Clinical Trials Arena team also investigate assets in ophthalmology, genitourinary system, immunology and oncology indications.
Pipeline Moves: Hengrui Medicine Phase III breast cancer termination lowers approval prospects
The Clinical Trials Arena team also review assets in the central nervous system, cardiology, renal, haematological and other oncology indications.
Pipeline Moves: Pfizer terminates glomerulosclerosis trial, advancement prospects drop
The Clinical Trials Arena Team also review assets in oncology, ophthalmology, genetic and non-malignant disorders.
Pipeline Moves: late-stage oncology trial terminations, approval prospects plunge
The Clinical Trials Arena team also look at assets in other oncology indications, metabolic and cardiovascular disorders.
Pipeline Moves: Regeneron terminates pancreatitis trial, advancement prospects drop
The Clinical Trials Arena team also investigate assets in esophagitis, psychiatric disorders and oncology indications.
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
Pipeline Moves: advancement prospects jump for Parkinson’s disease stem cell therapy
The Clinical Trials Arena team also review assets in asthma, multiple oncology indications and blood disorder.
Pipeline Moves: advancement prospects slump for lupus drug after negative topline data
The Clinical Trials Arena team also review assets in keratitis, dermatitis, obesity and oncology indications.
Pipeline Moves: positive topline results for epilepsy drug, advancement prospects jump
The Clinical Trials Arena team also investigate terminations in cholestasis, oncology, kidney disorder, and malaria.
Pipeline Moves: advancement prospects jump for cardiovascular gene therapy
The Clinical Trials Arena team also review investigational drugs in metabolic disorders, oncology, and plaque psoriasis.
Pipeline Moves: Trial completion bumps advancement prospects for AstraZeneca’s oncology drug
The Clinical Trial Arena team also investigate other assets in oncology, Gaucher disease, bacterial infection, and diabetic eye and kidney disease.